COVAXX and Aurobindo Pharma Announce COVID-19 Vaccine Partnership
The Pharma Data
DECEMBER 23, 2020
COVAXX is currently completing a Phase 1 clinical trial of UB-612 in Taiwan and will begin Phase 2/3 clinical trials in Asia, Latin America and the U.S. This agreement is in addition to the recently announced advanced purchase commitments of more than 140 million doses of COVAXX’s UB-612 vaccine, totaling over $2.8 About COVAXX.
Let's personalize your content